MSCs are a diverse type of mesenchymal stem cell that can be isolated from a variety of adult tissues, such as umbilical cord, endometrial polyps, bone marrow, adipose tissue, and others.
The presence of MSCs has recently been observed in other sources, such as menstrual blood. These MSCs are proving to be a noteworthy option for future clinical and experimental applications, and it is likely that there are more MSC sources yet to be discovered. One of the most challenging tasks is elucidating the mechanisms of MSC differentiation, mobilization,
and homing. The multipotent properties of MSCs make them a promising option for developing clinical applications. Several studies have also observed anti-inflammatory activity in MSCs. Notably, MSCs have the ability to downregulate the expression of the proinflammatory cytokines IL-1β, IL-6, and TNF-α, a major contributor to the development of depression, as discussed in Cytokine.
The antidepressant-like effect of human umbilical cord mesenchymal stem cells (HUC-MSCs) on microglia polarization and depression-like symptoms associated with myocardial infarction (MI) was investigated. The researchers concluded that injecting HUC-MSCs into a seven-week-old male mouse model significantly improved cardiac function and depression-like behavior caused by myocardial infarction. The researchers concluded that injecting HUC-MSCs into a seven-week-old male mouse model significantly improved cardiac function and depression-like behavior caused by myocardial infarction. This was achieved by reducing Jmjd3 levels and regulating M1/M2 microglia polarization.
HUC-MSCs may offer more significant benefits for patients with depression and MI than conventional antidepressants. Most antidepressants modulate monoamine transmission, yet many patients experience low residual symptoms and poor recovery rates. Recent research suggests that glutamatergic and glial abnormalities, as well as monoaminergic system disorders, are also implicated in the treatment of MI. Altered levels of glutamate have been observed in plasma, serum, cerebrospinal fluid, and brain tissue in suicide victims and individuals with mood disorders. Animal models of induced depression, such as the genetic mouse model of depression, demonstrate this. Several glutamatergic drugs have been proposed as potential antidepressants, although their sedative and psychotic side effects may limit their use. A study by Schwartz et al. found that when human MSCs expressing high levels of EAAT1 and EAAT2 were injected intracerebroventricularly into FSL mice, they exhibited prolonged depression-like behavior that mitigated these animals' effects, affecting motivation, novelty exploration, and pleasure. In recent research, nanoparticles (NPs) are being used as a therapeutic tool to treat and diagnose several neurological and mood disorders.
